Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTB NASDAQ:JAN NASDAQ:JMAC NASDAQ:OTLK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$1.72-7.5%$0.99$0.51▼$1.89$103.34M-0.266,519 shs262,179 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsJMACMaxpro Capital Acquisition$6.45+7.3%$6.18$7.50▼$19.22$145.16M0.0174,040 shs6,147 shsOTLKOncobiologics$2.18-5.6%$1.82$0.87▼$8.70$77.54M0.25860,024 shs860,975 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma-7.53%+13.16%+71.98%+132.68%+33.33%JANJanOne0.00%0.00%0.00%0.00%0.00%JMACMaxpro Capital Acquisition+7.32%+13.16%+1.49%+8.40%+3,093.07%OTLKOncobiologics-5.63%+5.31%+29.76%+50.34%-75.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma2.5811 of 5 stars3.53.00.00.02.32.50.0JANJanOneN/AN/AN/AN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AOTLKOncobiologics2.546 of 5 stars3.44.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.00Buy$7.00306.98% UpsideJANJanOne 0.00N/AN/AN/AJMACMaxpro Capital Acquisition 0.00N/AN/AN/AOTLKOncobiologics 2.80Moderate Buy$9.60340.37% UpsideCurrent Analyst Ratings BreakdownLatest JAN, CNTB, OTLK, and JMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.006/6/2025OTLKOncobiologicsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $21.005/20/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$26.03M3.67N/AN/A$1.67 per share1.03JANJanOne$39.61M0.00N/AN/A($0.67) per share0.00JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/A($3.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)JANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/AJMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AOTLKOncobiologics-$75.37M-$0.91N/AN/AN/AN/AN/A-271.12%8/13/2025 (Estimated)Latest JAN, CNTB, OTLK, and JMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025OTLKOncobiologics-$0.42N/AN/AN/A$1.66 millionN/A5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/15/2025Q2 2025OTLKOncobiologics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect Biopharma0.0110.2510.25JANJanOneN/A0.150.15JMACMaxpro Capital AcquisitionN/AN/AN/AOTLKOncobiologicsN/A0.720.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%JANJanOne6.27%JMACMaxpro Capital Acquisition73.18%OTLKOncobiologics11.20%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%JANJanOne3.00%JMACMaxpro Capital Acquisition19.27%OTLKOncobiologics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionableJANJanOne1708.98 million8.71 millionNot OptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableOTLKOncobiologics2033.57 million31.96 millionOptionableJAN, CNTB, OTLK, and JMAC HeadlinesRecent News About These CompaniesBrokerages Set Oncobiologics, Inc. (NASDAQ:OTLK) Target Price at $9.60July 14, 2025 | americanbankingnews.comOncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 11, 2025 | marketbeat.comOncobiologics (NASDAQ:OTLK) Trading Up 4.5% - Still a Buy?July 8, 2025 | marketbeat.comOTLK Outlook Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comOutlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive OfficerJuly 1, 2025 | globenewswire.comOutlook Therapeutics to Participate in a Virtual Investor Lunch Break EventJune 18, 2025 | globenewswire.comMicrosoft shares temp fix for Outlook crashes when opening emailsJune 17, 2025 | bleepingcomputer.comBCFA Institute 2025 Graduate Outlook Survey: Finance Top Career ChoiceJune 12, 2025 | tmcnet.comSteve Wilks Pleased With Jets Defensive OutlookJune 12, 2025 | msn.comMicrosoft Outlook to block more risky attachments used in attacksJune 12, 2025 | bleepingcomputer.comBOutlook’s wet AMD treatment accepted by SMC for NHS ScotlandJune 11, 2025 | pharmaceutical-technology.comPOutlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | finanznachrichten.deOutlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | globenewswire.comHighlights | Outlook Planet’s C³ Summit & Awards 2025June 7, 2025 | outlookbusiness.comONatural Gas Price Outlook – Natural Gas Continues to See Same Resistance LevelJune 7, 2025 | fxempire.comFOilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 MomentJune 7, 2025 | msn.comChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New PricingJune 7, 2025 | techrepublic.comTOutlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMDJune 3, 2025 | pharmabiz.comPOutlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMDJune 2, 2025 | globenewswire.comOutlook Therapeutics announces public stock offeringMay 24, 2025 | investing.comOutlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and WarrantsMay 24, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesBy Chris Markoch | June 21, 2025View Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesJAN, CNTB, OTLK, and JMAC Company DescriptionsConnect Biopharma NASDAQ:CNTB$1.72 -0.14 (-7.53%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.68 -0.03 (-2.03%) As of 07/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Maxpro Capital Acquisition NASDAQ:JMAC$6.45 +0.44 (+7.32%) As of 07/17/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Oncobiologics NASDAQ:OTLK$2.18 -0.13 (-5.63%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.22 +0.04 (+2.06%) As of 07/18/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
